MX2013000876A - Dihidroxi-clorinas glico-sustituidas y clorinas beta-funcionalizadas para terapia fotodinamica anti-microbiana. - Google Patents

Dihidroxi-clorinas glico-sustituidas y clorinas beta-funcionalizadas para terapia fotodinamica anti-microbiana.

Info

Publication number
MX2013000876A
MX2013000876A MX2013000876A MX2013000876A MX2013000876A MX 2013000876 A MX2013000876 A MX 2013000876A MX 2013000876 A MX2013000876 A MX 2013000876A MX 2013000876 A MX2013000876 A MX 2013000876A MX 2013000876 A MX2013000876 A MX 2013000876A
Authority
MX
Mexico
Prior art keywords
chlorins
functionalized
glyco
conjugates
photodynamic therapy
Prior art date
Application number
MX2013000876A
Other languages
English (en)
Other versions
MX352281B (es
Inventor
Daniel Aicher
Volker Albrecht
Burkhard Gitter
Christian B W Stark
Arno Wiehe
Original Assignee
Ceramoptec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramoptec Gmbh filed Critical Ceramoptec Gmbh
Priority claimed from PCT/US2011/045063 external-priority patent/WO2013015774A1/en
Publication of MX2013000876A publication Critical patent/MX2013000876A/es
Publication of MX352281B publication Critical patent/MX352281B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan conjugados moleculares antimicrobianos para el tratamiento y prevención de enfermedades infecciosas provocadas por microrganismos patogénicos en humanos y animales. La clave para estos conjugados es conectar dihidroxiclorinas o clorinas B-funcionalizadas con fracciones de carbohidrato. Estos conjugados resultan ser muy efectivos en el combate de las infecciones bacterianas provocadas por bacterias gram-positivas y gram-negativas, incluyendo sus cepas resistentes. De manera importante, también son efectivos en entornos complejos, incluyendo sangre, suero y otros fluidos corporales que están presentes en el cuerpo de un paciente. También se proporciona un método de uso para controlar los microrganismos patogénicos en humanos y animales.
MX2013000876A 2010-07-22 2011-07-22 Dihidroxi-clorinas glico-sustituidas y clorinas beta-funcionalizadas para terapia fotodinamica anti-microbiana. MX352281B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36671810P 2010-07-22 2010-07-22
PCT/US2011/045063 WO2013015774A1 (en) 2011-07-22 2011-07-22 Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy

Publications (2)

Publication Number Publication Date
MX2013000876A true MX2013000876A (es) 2013-04-30
MX352281B MX352281B (es) 2017-11-16

Family

ID=47006517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000876A MX352281B (es) 2010-07-22 2011-07-22 Dihidroxi-clorinas glico-sustituidas y clorinas beta-funcionalizadas para terapia fotodinamica anti-microbiana.

Country Status (7)

Country Link
US (1) US9308185B2 (es)
EP (1) EP2616065B1 (es)
CN (1) CN103096887B (es)
BR (1) BR112013001577B1 (es)
IL (1) IL224380A (es)
MX (1) MX352281B (es)
PL (1) PL2616065T3 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6041360B2 (ja) * 2011-07-22 2016-12-07 バイオリテック ウンターネーメンスベタイリグンクス ツヴァイ アクツィエンゲゼルシャフト 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン
US9156849B2 (en) * 2011-08-12 2015-10-13 Biolitec Pharma Marketing Ltd Application of β-functionalized dihydroxy-chlorins for PDT
CN103285403B (zh) * 2013-06-21 2015-03-04 苏州大学 一种络合卟啉含糖光敏剂及其制备方法
WO2016051361A1 (en) 2014-09-30 2016-04-07 Biolitec Unternehmensbeteiligungs Ii Ag Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN111701144B (zh) 2015-07-28 2023-03-21 诺欧生物有限责任公司 用于对一氧化氮的光疗调节的系统和方法
EP3210626A1 (en) 2016-02-26 2017-08-30 biolitec Unternehmensbeteiligungs II AG Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
WO2020120474A1 (en) 2018-12-10 2020-06-18 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
US11986666B2 (en) 2020-03-19 2024-05-21 Know Bio, Llc Illumination devices for inducing biological effects
US11147984B2 (en) 2020-03-19 2021-10-19 Know Bio, Llc Illumination devices for inducing biological effects
US11654294B2 (en) 2021-03-15 2023-05-23 Know Bio, Llc Intranasal illumination devices

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005025A (en) * 1959-08-07 1961-10-17 American Cyanamid Co Preparation of neutral chlortetracycline
FR2709491B1 (fr) * 1993-09-03 1995-10-27 Centre Nat Rech Scient Nouveaux dérivés de porphyrines et leurs applications notamment en thérapeutique.
EP1279676A1 (en) * 2001-07-19 2003-01-29 Institut Curie Porphyrin derivatives for photodynamic therapy
US7110533B2 (en) * 2004-05-18 2006-09-19 Time Warner Cable, Inc. Telephone NID isolation module
EP3459955B1 (en) * 2008-09-18 2022-11-02 biolitec Unternehmensberatungs II AG Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt
PL2870159T3 (pl) * 2010-07-22 2018-01-31 Biolitec Unternehmensbeteiligungs Ii Ag Zastosowanie β-funkcjonalizowanych dihydroksychloryn do PDT

Also Published As

Publication number Publication date
EP2616065A4 (en) 2014-05-14
CN103096887A (zh) 2013-05-08
EP2616065B1 (en) 2017-11-01
IL224380A (en) 2017-06-29
EP2616065A1 (en) 2013-07-24
CN103096887B (zh) 2017-12-29
BR112013001577B1 (pt) 2021-05-04
US9308185B2 (en) 2016-04-12
US20120263625A1 (en) 2012-10-18
BR112013001577A2 (pt) 2017-12-12
PL2616065T3 (pl) 2018-05-30
MX352281B (es) 2017-11-16

Similar Documents

Publication Publication Date Title
MX352281B (es) Dihidroxi-clorinas glico-sustituidas y clorinas beta-funcionalizadas para terapia fotodinamica anti-microbiana.
Batabyal et al. Methicillin-resistant Staphylococcus aureus: A brief review
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
NZ593111A (en) Antibacterial compounds
IL224048B (en) Antigenic preparation containing e cells. killed or attenuated pathogenic coli, for subcutaneous or transdermal administration for the treatment of Crohn's disease in humans
BR0209975A (pt) ácido lipoteicóico de bactérias de ácido lático e seu uso para modular respostas imunes mediadas por bactérias gram-negativas, potenciais bactérias gram-positivas patogênicas
ATE528311T1 (de) Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
WO2008036761A8 (en) Anti-microbial defensin-related peptides and methods of use
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2010125196A3 (en) Bacteriophages specific to pak and cha strains of pseudomonas aeruginosa and their applications
MX344183B (es) Proteina antimicrobiana.
CN107320466A (zh) 厚朴酚在制备ndm‑1酶抑制剂中的医用用途
Kot Virulence factors and innovative strategies for the treatment and control of uropathogenic Escherichia coli
WO2015100448A3 (en) Multimodal antimicrobial therapy
CN102754666A (zh) 医疗机构物体表面草本消毒剂
Richter Tackling superbugs in their slime castles: innovative approaches against antimicrobial-resistant biofilm infections
MX2009001074A (es) Terapia fotodinamica antimicrobiana.
GB0114672D0 (en) Pharmaceutical formulations and methods of medical treatment
WO2010141143A3 (en) Engineered avirulent bacteria strains and use in medical treatments
PL2037949T3 (pl) Sposób wytwarzania preparatu o nazwie czynnik przekazu
BR112014005221A2 (pt) uso de materiais de fibra oca modificada para a remoção de exotoxinas produzidas por escherichia coli a partir de liquidos, de preferência a partir de sangue e de plasma, bem como seu uso para o tratamento de doenças concomitantes

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG

FG Grant or registration